Audited Financials Results for the quarter and year ended 31.03.2025
Awaiting price reaction for this filing.
Sangam Health Care Products Ltd reported audited FY25 results with revenue from operations of ₹1,245.96 lakhs, a marginal ~2.9% increase over ₹1,210.84 lakhs in FY24. The company slipped into a net loss after tax for the full year (against a marginal profit of ~₹0.08 lakh in FY24), as deferred tax of ₹23.32 lakhs ate into a profit before tax of ₹25.46 lakhs. The balance sheet remains deeply stressed: total equity is negative at ₹(2,006.06) lakhs due to accumulated losses of ₹3,492.13 lakhs, while total borrowings stand at ₹2,198.17 lakhs. Operating cash flow was healthy at ₹148.79 lakhs and the statutory auditor (M.M Reddy & Co.) issued an unqualified/unmodified opinion on the results.
Negative net worth combined with high borrowings raises serious solvency and going-concern concerns for shareholders despite a clean audit report. The swing to a net loss and lack of meaningful revenue growth suggest the stock remains a high-risk, deeply distressed micro-cap investment.